[1] de Gottardi A, Rautou P E, Schouten J, et al. Porto-sinusoidal vascular disease: proposal and description of a novel entity [J]. Lancet Gastroenterol Hepatol, 2019, 4(5): 399-411.
[2] Kim H P, Navarro V, Zacks S, et al. The clinical spectrum and diagnosis of oxaliplatin liver injury in the era of nonalcoholic fatty liver disease [J]. Clin Gastroenterol Hepatol, 2021, 19(10): 2199-2201.
[3] Puente A, Fortea J I, del Pozo C, et al. Clinical and genetic factors involved in porto-sinusoidal vascular disorder after oxaliplatin exposure [J]. Dig Liver Dis, 2024, 56(10): 1721-1729.
[4] Schouten J N, van der Ende M E, Ko?ter T, et al. Risk factors and outcome of HIV-associated idiopathic noncirrhotic portal hypertension [J]. Aliment Pharmacol Ther, 2012, 36(9): 875-885.
[5] Giuli L, Pallozzi M, Venturini G, et al. Molecular mechanisms underlying vascular liver diseases: focus on thrombosis [J]. Int J Mol Sci, 2023, 24(16):12754.
[6] Elkrief L, Ferrusquia-Acosta J, Payancé A, et al. Abdominal surgery in patients with idiopathic noncirrhotic portal hypertension: a multicenter retrospective study [J]. Hepatology, 2019, 70(3): 911-924.
[7] Gioia S, Carnevale R, Tavano D, et al. Association between gut-derived endotoxins and porto-sinusoidal vascular disorder with portal hypertension [J]. Aliment Pharmacol Ther, 2023, 58(11-12): 1205-1216.
[8] Magaz M, Giudicelli-Lett H, Abraldes J G, et al. Porto-sinusoidal vascular liver disorder with portal hypertension: natural history and long-term outcome [J]. J Hepatol, 2025, 82(1): 72-83.
[9] Corvilain E, Gérard L, Fadlallah J, et al. Porto-sinusoidal vascular disease is associated with gastrointestinal disorders in common variable immunodeficiency [J]. J Clin Immunol, 2026, 46(1):29.
[10] Ciriaci N, Bertin L, Rautou P E. Genetic predisposition to porto-sinusoidal vascular disorder [J]. Hepatology, 2026, 83(2): 409-424.
[11] 申梨, 段维佳, 吕婷婷, 等. 风湿性疾病与门静脉高压 [J]. 临床肝胆病杂志, 2025, 41(5): 812-816.
[12] Sidali S, Borie R, Sicre de Fontbrune F, et al. Liver disease in germline mutations of telomere-related genes: prevalence, clinical, radiological, pathological features, outcome, and risk factors [J]. Hepatology, 2024, 79(6): 1365-1380.
[13] Shan J, Megarbane A, Chouchane A, et al. Genetic predisposition to porto-sinusoidal vascular disorder: a functional genomic-based, multigenerational family study [J]. Hepatology, 2023, 77(2): 501-511.
[14] Khandakar B, Joldoshova A, Zhang X. Porto-sinusoidal vascular disease-like alterations in transplant liver biopsies: a clinicopathologic observation of transplant-associated portal vasculopathy [J]. Hum Pathol, 2026, 167: 105984.
[15] Cazals-Hatem D, Hillaire S, Rudler M, et al. Obliterative portal venopathy: portal hypertension is not always present at diagnosis [J]. J Hepatol, 2011, 54(3): 455-461.
[16] Zhang X, Durham K M, Garza A A, et al. Portal vein thrombosis, hepatic decompensation, and survival in patients with porto-sinusoidal vascular disease and portal hypertension [J]. J Gastroenterol, 2023, 58(3): 268-276.
[17] Ma L, Zhang G, Wang Y, et al. Porto-sinusoidal vascular disorder with known etiologies had more severe portal hypertension and poorer outcomes [J]. Dig Liver Dis, 2025, 57(3): 730-737.
[18] Zhang Y, Xiong Q, Zhong Y, et al. Clinical characteristics and natural history of porto-sinusoidal vascular disease: a cohort study of 234 patients in China [J]. Liver Int, 2024, 44(9): 2329-2340.
[19] 单姗, 马琳, 曾馨, 等. 肝细胞CK7染色阳性与门静脉肝窦血管病临床病理表型的相关性分析 [J]. 肝脏, 2026, 31(1): 81-88.
[20] 中国研究型医院学会肝病专业委员会, 中国研究型医院学会介入医学专业委员会, 北京医师协会门静脉高压症多学科诊治医师分会. 肝脏血管性疾病诊治临床实践专家共识(2026年版) [J]. 临床肝胆病杂志, 2026, 42(1): 47-65.
[21] 蔡子豪, 诸葛宇征. 门静脉肝窦血管性疾病的疾病特点与诊疗进展 [J]. 肝脏, 2023, 28(2): 148-151. |
